Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Martin C, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Kowalyszyn R, Magri I, Varela M, Richardet E, Vera K, Foglia S, Jerez I, Aman E, Martinengo G, Batagelj E, Dri A, Pilnik N, Roa GM, Mando P, Tsou F, Recondo G, Cayol F, Flores M, Sena S, Bagnes C, Waisberg FD, Minatta JN, Rizzo M. Martin C, et al. Among authors: bagnes c. Clin Lung Cancer. 2020 Sep;21(5):e380-e387. doi: 10.1016/j.cllc.2020.02.014. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32213298
Multidisciplinary approach to COVID-19 and cancer: consensus from scientific societies in Argentina.
Ismael J, Losco F, Quildrian S, Sanchez P, Pincemin I, Lastiri J, Bella S, Chinellato A, Dellamea G, Ahualli A, Rompato S, Velez J, Escobar R, Zwenger A, Rosales C, Bagnes C, Puyol J, Niewiadomski D, Smecuol E, Nachman F, Gonzalez E, Ferraris G, Suppicich JR, Price P, Medina L, O'Connor J. Ismael J, et al. Among authors: bagnes c. Ecancermedicalscience. 2020 May 13;14:1044. doi: 10.3332/ecancer.2020.1044. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32565897 Free PMC article.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.